Provided by Tiger Trade Technology Pte. Ltd.

H. Lundbeck A/S

6.21
0.0000
Volume:- -
Turnover:- -
Market Cap:6.16B
PE:17.66
High:6.21
Open:6.21
Low:6.21
Close:6.21
52wk High:7.55
52wk Low:4.42
Shares:992.01M
Float Shares:305.97M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.15
Dividend Rate:2.40%
EPS(TTM):0.3515
EPS(LYR):0.3423
ROE:12.79%
ROA:6.70%
PB:1.68
PE(LYR):18.14

Loading ...

Company Profile

Company Name:
H. Lundbeck A/S
Exchange:
PINK LIMITED
Establishment Date:
1915
Employees:
5039
Office Location:
Ottiliavej 9,Valby,Capital Region of Denmark,Denmark
Zip Code:
2500
Fax:
45 36 30 19 40
Introduction:
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.